share_log

CRISPR Therapeutics | 8-K: Current report

CRISPR Therapeutics | 8-K: Current report

CRISPR Therapeutics | 8-K：重大事件
美股sec公告 ·  05/23 08:20
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.
CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.
CRISPR Therapeutics AG宣布任命朱丽安·布鲁诺为新任首席运营官，自2024年5月23日起生效。布鲁诺自2019年4月起在公司工作，此前曾担任高级副总裁兼项目与投资组合管理主管。她的晋升是在成功监督与Vertex Pharmicals的血红蛋白病合作计划以及该公司的免疫肿瘤学试验之后获得的。布鲁诺的新雇佣协议包括46万美元的年薪，有资格参加公司的年度奖金计划，目标奖金为其基本工资的45％，以及一次性发放20,000个限制性股票单位。该协议还概述了终止条款，并规定了六个月的通知期，其中规定了12个月的通知期，如果控制权变更后终止，则立即授予股权奖励。该公司以附录10.1的形式向美国证券交易委员会提交了雇佣协议的全文。
CRISPR Therapeutics AG宣布任命朱丽安·布鲁诺为新任首席运营官，自2024年5月23日起生效。布鲁诺自2019年4月起在公司工作，此前曾担任高级副总裁兼项目与投资组合管理主管。她的晋升是在成功监督与Vertex Pharmicals的血红蛋白病合作计划以及该公司的免疫肿瘤学试验之后获得的。布鲁诺的新雇佣协议包括46万美元的年薪，有资格参加公司的年度奖金计划，目标奖金为其基本工资的45％，以及一次性发放20,000个限制性股票单位。该协议还概述了终止条款，并规定了六个月的通知期，其中规定了12个月的通知期，如果控制权变更后终止，则立即授予股权奖励。该公司以附录10.1的形式向美国证券交易委员会提交了雇佣协议的全文。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息